- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07950111
HA380 Hemoadsorption Combined With Continuous Renal Replacement Therapy Versus Continuous Renal Replacement Therapy Alone in Septic Shock (HA380-SHOCK)
Efficacy of Continuous Renal Replacement Therapy Combined With the HA380 Hemoadsorption Cartridge Versus Continuous Renal Replacement Therapy Alone in the Treatment of Septic Shock: A Single-Center, Open-Label, Assessor-Blinded, Randomized Controlled Trial
The goal of this clinical trial is to learn whether adding an HA380 hemoadsorption cartridge to continuous renal replacement therapy (CRRT) helps adults with septic shock and acute kidney injury requiring CRRT recover from shock better than CRRT alone. Septic shock is a life-threatening condition in which an infection triggers an excessive inflammatory response, causing very low blood pressure and organ failure. The HA380 cartridge is a device placed in the CRRT blood circuit that is designed to remove inflammatory molecules (cytokines) from the blood.
The main question it aims to answer is: Does CRRT combined with the HA380 cartridge result in a lower blood lactate level (a marker of poor oxygen delivery to the body's tissues) at 24 hours than CRRT alone? Researchers will also compare the two groups in terms of the amount of blood-pressure-supporting medicines needed, blood levels of inflammatory cytokines, organ function, time to recovery from shock, need for organ support, length of intensive care unit (ICU) and hospital stay, survival up to 28 days, and side effects.
Participants will:
- Be randomly assigned to receive either CRRT combined with the HA380 cartridge or CRRT alone, in addition to the same standard septic shock care
- If assigned to the HA380 group, receive three HA380 cartridges consecutively, each for 6 hours (18 hours in total), followed by CRRT alone as needed
- Have their vital signs, medicine doses and blood tests recorded before treatment and at set times up to day 7
- Be followed up for survival and recovery until day 28
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Background: Septic shock remains a leading cause of death in ICUs. Excessive release of inflammatory cytokines ("cytokine storm") contributes to vasoplegia, tissue hypoperfusion and multiple organ dysfunction. The HA380 cartridge (Jafron Biomedical, China) is a neutral macroporous resin hemoadsorption device that removes middle-molecular-weight substances, including cytokines, and can be used in series with a CRRT circuit. It is licensed for clinical use in Vietnam by the Ministry of Health (Decision No. 266/QD-BYT, 22 January 2025). Available data on HA380 combined with CRRT in septic shock come mainly from retrospective single-center studies, and randomized evidence is lacking. The Surviving Sepsis Campaign 2026 guidelines issue a weak recommendation against the routine use of blood purification therapies, including hemoperfusion, in sepsis and septic shock, reflecting the limited and uncertain evidence. This trial addresses that evidence gap in a selected population with marked hyperinflammation (IL-6 >500 pg/mL), septic shock requiring high-dose vasopressors and acute kidney injury already requiring CRRT, in whom HA380 can be added to an existing extracorporeal circuit. HA380 is used only within this randomized trial, under Ethics Committee approval and written informed consent.
Objectives: (1) to compare the effects of CRRT combined with HA380 hemoadsorption versus CRRT alone on tissue perfusion, hemodynamics, inflammation and organ function in septic shock; (2) to describe clinical outcomes and safety of the two strategies.
Design: Prospective, single-center, open-label, assessor-blinded, randomized controlled trial with two parallel groups (1:1), conducted in the Medical and Toxicological Intensive Care Unit, 108 Military Central Hospital, Hanoi, Vietnam. Planned recruitment: November 2026 to October 2028, with follow-up to November 2028. The study is part of a doctoral (PhD) program of the 108 Institute of Clinical Medical and Pharmaceutical Sciences.
Participants: Adults with septic shock (Sepsis-3) requiring norepinephrine ≥0.4 µg/kg/min (or equivalent), with plasma interleukin-6 (IL-6) >500 pg/mL (Elecsys IL-6, Cobas system) and acute kidney injury with at least one indication for CRRT.
Randomization, allocation concealment and blinding: After written informed consent (from the patient or legally authorized representative), participants are randomized 1:1 by permuted-block randomization with randomly varying block sizes. The sequence is generated in R (blockrand package) by an independent person not involved in recruitment or treatment, and concealed in sequentially numbered, opaque, sealed envelopes (SNOSE). Treating clinicians cannot be blinded. The person scoring SOFA and SOFA-2, the laboratory staff performing cytokine assays and the statistician are blinded to allocation. To limit bias from the open-label design, vasoactive drugs are titrated in both groups by the same written protocol based on invasive arterial pressure (MAP target ≥65 mmHg, or ≥60 mmHg in patients aged ≥65 years; vasopressors are weaned in the following order: epinephrine, norepinephrine, and then vasopressin).
Interventions: Apart from the study intervention, both groups receive the same standard septic shock management according to the Surviving Sepsis Campaign 2026 guidelines and baseline CRRT started as soon as possible after randomization (within 2 hours): continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (each M100 used for a maximum of 24 hours), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, and unfractionated heparin anticoagulation per study protocol (no anticoagulation if platelet count <50 ×10⁹/L). In the intervention group, the HA380 cartridge is connected in series after the M100 hemofilter, before blood returns to the patient; three HA380 cartridges are used consecutively for 6 hours each (18 hours of hemoadsorption), after which CRRT alone continues as clinically indicated. If a cartridge clots early, it is removed without replacement, CRRT continues, and the next cartridge is connected at the next scheduled time. Full adherence is defined as use of all three cartridges per protocol with a total hemoadsorption time of at least 16 hours. To limit antibiotic underdosing, loading doses are given before HA380 connection when possible, vancomycin and aminoglycoside levels are monitored in both groups when available, and all antibiotics given in the first 24 hours are recorded.
Time points: R = randomization (time-to-event outcomes are counted from R). T0 = immediately before the first CRRT session (≤2 hours after R). Hemodynamics, vasoactive doses (summarized as VIS and norepinephrine equivalent dose, NEE) and arterial blood gases including lactate (RAPIDPoint 500 analyzer in the ICU, same device for all measurements) are recorded at T0 and at 6, 12, 18, 24, 48 and 72 hours after CRRT initiation. Plasma IL-1β, IL-6, IL-8, IL-10 and TNF-α are measured at T0 and 24 hours (Luminex 200, ProcartaPlex multiplex immunoassay, Vietnam Military Medical University). Hematology, liver and renal function, coagulation, CRP, procalcitonin, ferritin, LDH, SOFA and SOFA-2 scores and the number of organ failures (Knaus criteria) are assessed at T0, day 3 and day 7. APACHE II, SAPS II and mNUTRIC are recorded at baseline. Clinical outcomes are followed to day 28 (D28).
Sample size: Based on An et al. (2025), the mean reduction in lactate after 24 hours of treatment was 1.61 versus 1.04 mmol/L (difference 0.57 mmol/L; pooled SD of 24-hour lactate 0.81 mmol/L; standardized effect size d ≈ 0.70). With two-sided α = 0.05 and 80% power, 32 participants per group are required; inflated by approximately 9% for attrition, 35 per group (70 in total) will be enrolled.
Statistical analysis: The statistical analysis plan is finalized before database lock and before unblinding of the statistician. The primary analysis is intention-to-treat (all randomized participants analyzed as allocated). The primary outcome (arterial lactate at 24 hours) is analyzed by ANCOVA with treatment group and baseline lactate, reporting the adjusted mean difference with 95% CI; participants who die before 24 hours are assigned the highest lactate value observed in the whole sample. Pre-specified sensitivity analyses: (1) log-transformed lactate; (2) additional adjustment for baseline log IL-6, SOFA and epinephrine dose; (3) survivors to 24 hours only; (4) hierarchical rank test (death before 24 hours ranked worst, survivors ranked by lactate); (5) per-protocol population. Repeated secondary measures are analyzed with linear mixed models adjusted for baseline; time to shock resolution with a Fine-Gray competing-risk model (death as competing event); mortality and dialysis dependence with risk ratios, risk differences, Kaplan-Meier, log-rank and Cox models; free-day outcomes with Mann-Whitney U and Hodges-Lehmann estimates; Holm correction across the five cytokines. Pre-specified subgroup: baseline IL-6 below/above the sample median (interaction test). Baseline IL-6 used for the subgroup analysis and sensitivity analysis (2) is the value measured by Elecsys IL-6 at screening (the same assay used for eligibility). No randomized participant is excluded from the primary (intention-to-treat) analysis.
Safety: Adverse events are defined using pre-specified study criteria and graded with CTCAE version 6.0; for abnormalities already present at baseline (e.g., thrombocytopenia, electrolyte disturbances), only treatment-emergent events are counted: a new event of grade ≥1 after T0 in a participant with grade 0 at T0, or worsening by at least one grade from T0. Monitoring windows: hypotension within 30 minutes after CRRT connection and after each HA380 cartridge change (6, 12 and 18 hours); bleeding, thrombocytopenia and hemolysis up to day 7; electrolyte disturbances until the end of CRRT or day 7, whichever comes first; hypothermia by hourly core temperature during CRRT (lowest value recorded every 6 hours in the first 24 hours, then daily) until the end of CRRT or day 7, whichever comes first; anaphylaxis within 72 hours; catheter occlusion, catheter-site infection and catheter-related venous thrombosis daily up to day 14. Extracorporeal circuit incidents (hemofilter membrane rupture, hemofilter clotting, early HA380 clotting, technical machine stoppage) are classified as device deficiencies, defined by objective machine-alarm and observation criteria, and recorded in real time with the machine alarm log until the end of CRRT or 72 hours after CRRT initiation, whichever comes first. Serious adverse events are reported to the Ethics Committee according to national regulations.
Ethics, funding and conflicts of interest: The protocol was approved by the Ethics Committee in Biomedical Research, 108 Military Central Hospital (Certificate No. 7197/GCN-BV, 11 September 2026). HA380 cartridges and cytokine assays are funded by Thanh Phuong Co., Ltd., the Vietnamese distributor of HA380 (donation letter No. 0805/CV-TPC, 8 May 2026). The company has no role in study design, data collection, data analysis, interpretation of results, manuscript preparation or the decision to publish. Participants incur no additional costs.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Bui Viet Hoan, MD
- Номер телефона: +84 987 649 061
- Электронная почта: bvhoan108@gmail.com
Места учебы
-
-
-
Hanoi, Вьетнам
- The 108 Military Central Hospital
-
Контакт:
- Bui Viet Hoan, MD
- Номер телефона: +84 987 649 061
- Электронная почта: bvhoan108@gmail.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Age ≥18 years
- Septic shock according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, 2016)
- Norepinephrine ≥0.4 µg/kg/min, or an equivalent vasopressor dose, required to maintain the target mean arterial pressure
- Plasma interleukin-6 (IL-6) concentration >500 pg/mL (Elecsys IL-6, Cobas system)
- Acute kidney injury with at least one indication for continuous renal replacement therapy: serum potassium ≥6.5 mmol/L; pH <7.2 not due to pure respiratory acidosis; oliguria <0.3 mL/kg/h for ≥24 hours or anuria for ≥12 hours; fluid overload unresponsive to diuretics, or pulmonary edema; or uremic syndrome
- Randomization within 24 hours of septic shock onset
- Written informed consent obtained from the patient or the legally authorized representative
Exclusion Criteria:
- Pregnancy or breastfeeding
- Malignancy currently treated with chemotherapy or radiotherapy, neutrophil count <1 ×10⁹/L, immunosuppressive therapy after organ transplantation, or AIDS
- Chronic kidney disease on maintenance dialysis, Child-Pugh C cirrhosis, or NYHA class IV heart failure
- Active bleeding, or platelet count <20 ×10⁹/L refractory to platelet transfusion
- Allergy to heparin or history of heparin-induced thrombocytopenia
- Concomitant hemorrhagic shock or anaphylactic shock
- Expected death within 24 hours, or a do-not-resuscitate order or a family decision to withdraw life-sustaining treatment
- Cardiac arrest during the current illness before randomization
- Continuous renal replacement therapy or any hemoadsorption already received during the current hospital admission before randomization
- Patient or legally authorized representative declines participation
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: CRRT + HA380 Hemoadsorption
Baseline CRRT (CVVHDF, Prismaflex, M100 hemofilter) plus three consecutive HA380 cartridges, 6 hours each (18 hours in total), connected in series after the M100 hemofilter; CRRT alone continues afterwards as clinically indicated. Standard septic shock care per the Surviving Sepsis Campaign 2026 guidelines. |
Single-use neutral macroporous resin hemoadsorption cartridge (Jafron Biomedical), primed with heparinized saline according to the manufacturer's instructions and connected in series after the M100 hemofilter, before blood returns to the patient. Three cartridges are used consecutively, each for 6 hours (total 18 hours), starting with the first CRRT session
Другие имена:
Continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (maximum 24 hours per filter), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, unfractionated heparin anticoagulation per protocol (no anticoagulation if platelet count <50 ×10⁹/L); started within 2 hours of randomization.
Другие имена:
|
|
Активный компаратор: CRRT Alone
Baseline CRRT (CVVHDF, Prismaflex, M100 hemofilter) without hemoadsorption. Standard septic shock care per the Surviving Sepsis Campaign 2026 guidelines. |
Continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (maximum 24 hours per filter), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, unfractionated heparin anticoagulation per protocol (no anticoagulation if platelet count <50 ×10⁹/L); started within 2 hours of randomization.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Arterial Blood Lactate Concentration at 24 Hours
Временное ограничение: Baseline and 24 hours after initiation of CRRT
|
Arterial blood lactate (mmol/L) measured by blood gas analyzer 24 hours after initiation of CRRT, compared between groups by analysis of covariance (ANCOVA) adjusted for baseline lactate. Participants who die before 24 hours are assigned the highest lactate value observed in the study sample. |
Baseline and 24 hours after initiation of CRRT
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Vasoactive-Inotropic Score (VIS)
Временное ограничение: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
VIS = dopamine (µg/kg/min) + dobutamine (µg/kg/min) + 100 × epinephrine (µg/kg/min) + 100 × norepinephrine (µg/kg/min) + 10 × milrinone (µg/kg/min) + 10,000 × vasopressin (U/kg/min), according to Gaies et al. (Pediatr Crit Care Med 2010). Higher scores indicate greater vasoactive and inotropic support. Unit: points (dimensionless score). |
Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
|
Norepinephrine Equivalent Dose (NEE)
Временное ограничение: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
Total vasopressor dose expressed as norepinephrine equivalents (µg/kg/min), calculated as: NEE = norepinephrine (µg/kg/min) + epinephrine (µg/kg/min) + dopamine (µg/kg/min)/100 + phenylephrine (µg/kg/min)/10 + 2.5 × vasopressin (U/min), adapted from Kotani et al. (Crit Care 2023;27:29) and restricted to the vasopressors permitted in the study protocol. Norepinephrine doses are expressed as norepinephrine base; weight-based vasopressin doses are converted to U/min using the participant's body weight. Inotropes (dobutamine, milrinone) are not included. Higher values indicate greater vasopressor requirement. |
Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
|
Mean Arterial Pressure
Временное ограничение: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
Mean arterial pressure (mmHg) measured by invasive arterial monitoring. |
Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
|
Heart Rate
Временное ограничение: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
Heart rate (beats per minute). |
Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
|
Arterial Blood Lactate Concentration Over Time
Временное ограничение: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
Serial arterial blood lactate concentration (mmol/L) measured by blood gas analyzer at each time point. Lactate trajectories are compared between groups using a linear mixed-effects model for repeated measures adjusted for baseline lactate. |
Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
|
Lactate Clearance
Временное ограничение: 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
Lactate clearance (%) calculated at each time point as (baseline arterial lactate - arterial lactate at the time point) / baseline arterial lactate × 100. Positive values indicate a decrease in lactate from baseline; negative values indicate an increase. |
6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
|
Epinephrine Dose
Временное ограничение: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
Epinephrine infusion dose (µg/kg/min) |
Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT
|
|
Number of Participants Receiving Epinephrine in the First 24 Hours
Временное ограничение: From initiation of CRRT to 24 hours
|
Number of participants who receive an epinephrine infusion at any time during the first 24 hours of CRRT. |
From initiation of CRRT to 24 hours
|
|
Duration of Epinephrine Infusion in the First 24 Hours
Временное ограничение: From initiation of CRRT to 24 hours
|
Total duration (hours) of epinephrine infusion during the first 24 hours of CRRT. |
From initiation of CRRT to 24 hours
|
|
Number of Participants With Early Shock Reversal
Временное ограничение: 6, 12, 18, 24 and 48 hours after initiation of CRRT
|
Early shock reversal defined as mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) together with a decrease in arterial lactate of more than 20% from baseline. |
6, 12, 18, 24 and 48 hours after initiation of CRRT
|
|
Percentage Reduction in Plasma Interleukin-6 (IL-6)
Временное ограничение: Baseline and 24 hours after initiation of CRRT
|
Percentage reduction in plasma IL-6 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %. |
Baseline and 24 hours after initiation of CRRT
|
|
Percentage Reduction in Plasma Interleukin-1 Beta (IL-1β)
Временное ограничение: Baseline and 24 hours after initiation of CRRT
|
Percentage reduction in plasma IL-1β concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %. |
Baseline and 24 hours after initiation of CRRT
|
|
Percentage Reduction in Plasma Interleukin-8 (IL-8)
Временное ограничение: Baseline and 24 hours after initiation of CRRT
|
Percentage reduction in plasma IL-8 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %. |
Baseline and 24 hours after initiation of CRRT
|
|
Percentage Reduction in Plasma Interleukin-10 (IL-10)
Временное ограничение: Baseline and 24 hours after initiation of CRRT
|
Percentage reduction in plasma IL-10 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %. |
Baseline and 24 hours after initiation of CRRT
|
|
Percentage Reduction in Plasma Tumor Necrosis Factor Alpha (TNF-α)
Временное ограничение: Baseline and 24 hours after initiation of CRRT
|
Percentage reduction in plasma TNF-α concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %. |
Baseline and 24 hours after initiation of CRRT
|
|
Sequential Organ Failure Assessment (SOFA) Score
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
SOFA score (range 0-24; higher scores indicate more severe organ dysfunction), calculated by an assessor blinded to group allocation. |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
SOFA-2 Score
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
SOFA-2 score (range 0-24; higher scores indicate more severe organ dysfunction), calculated by an assessor blinded to group allocation. |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Number of Failing Organ Systems
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Number of failing organ systems (cardiovascular, respiratory, renal, hematological, neurological, hepatic) according to Knaus criteria. Range 0-6. |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Creatinine
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Blood creatinine concentration (µmol/L). |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Total Bilirubin
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Blood total bilirubin concentration (µmol/L). |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Platelet Count
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Platelet count (×10⁹/L). |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
International Normalized Ratio (INR)
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Prothrombin time expressed as INR. |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
C-Reactive Protein
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Blood C-reactive protein concentration (mg/L). |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Procalcitonin
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Blood procalcitonin concentration (ng/mL). |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Ferritin
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Blood ferritin concentration (ng/mL). |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Lactate Dehydrogenase (LDH)
Временное ограничение: Baseline, day 3 and day 7 after initiation of CRRT
|
Blood LDH activity (U/L). |
Baseline, day 3 and day 7 after initiation of CRRT
|
|
Time to Shock Resolution
Временное ограничение: From randomization to day 28
|
Time (hours) from randomization to discontinuation of the last vasopressor, with mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) maintained for at least 24 hours without vasopressors. Death before shock resolution is treated as a competing event. |
From randomization to day 28
|
|
Number of Participants With Shock Resolution
Временное ограничение: From randomization to day 28
|
Shock resolution defined as complete discontinuation of vasopressors with mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) maintained for at least 24 hours without reintroduction. |
From randomization to day 28
|
|
Number of Participants With Recurrent Shock
Временное ограничение: From randomization to day 28
|
Recurrent shock defined as reintroduction of vasopressors after shock resolution. |
From randomization to day 28
|
|
Vasopressor-Free Days
Временное ограничение: From randomization to day 28
|
Number of days alive and free of vasopressors within 28 days after randomization; participants who die before day 28 are assigned 0 days. |
From randomization to day 28
|
|
Ventilator-Free Days
Временное ограничение: From randomization to day 28
|
Number of days alive and free of invasive mechanical ventilation within 28 days after randomization; participants who die before day 28 are assigned 0 days. |
From randomization to day 28
|
|
Renal Replacement Therapy-Free Days
Временное ограничение: From randomization to day 28
|
Number of days alive and free of any renal replacement therapy within 28 days after randomization; participants who die before day 28 are assigned 0 days. |
From randomization to day 28
|
|
ICU-Free Days
Временное ограничение: From randomization to day 28
|
Number of days alive and out of the ICU within 28 days after randomization; participants who die before day 28 are assigned 0 days. |
From randomization to day 28
|
|
Number of Participants Dependent on Renal Replacement Therapy
Временное ограничение: Day 7 and day 28 after randomization
|
Dialysis dependence defined as still requiring any form of renal replacement therapy on the day of assessment. |
Day 7 and day 28 after randomization
|
|
Duration of Invasive Mechanical Ventilation
Временное ограничение: From randomization to ICU discharge, assessed up to 28 days
|
Number of days on invasive mechanical ventilation. |
From randomization to ICU discharge, assessed up to 28 days
|
|
Duration of CRRT
Временное ограничение: From initiation of CRRT to ICU discharge, assessed up to 28 days
|
Number of days on continuous renal replacement therapy. |
From initiation of CRRT to ICU discharge, assessed up to 28 days
|
|
Number of M100 Hemofilters Used
Временное ограничение: From initiation of CRRT to ICU discharge, assessed up to 28 days
|
Total number of M100 hemofilters used during the ICU stay. |
From initiation of CRRT to ICU discharge, assessed up to 28 days
|
|
Lifespan of the First M100 Hemofilter
Временное ограничение: From initiation of CRRT to 24 hours
|
Time (hours) from start of the first M100 hemofilter to its replacement (maximum 24 hours per protocol). |
From initiation of CRRT to 24 hours
|
|
ICU Length of Stay
Временное ограничение: From ICU admission to ICU discharge, assessed up to 28 days
|
Number of days from ICU admission to ICU discharge. |
From ICU admission to ICU discharge, assessed up to 28 days
|
|
Hospital Length of Stay
Временное ограничение: From hospital admission to hospital discharge, assessed up to 28 days
|
Number of days from hospital admission to hospital discharge. |
From hospital admission to hospital discharge, assessed up to 28 days
|
|
ICU Mortality
Временное ограничение: From randomization to ICU discharge, assessed up to 28 days
|
Number of participants who die from any cause during the ICU stay. |
From randomization to ICU discharge, assessed up to 28 days
|
|
In-Hospital Mortality
Временное ограничение: From randomization to hospital discharge, assessed up to 28 days
|
Number of participants who die from any cause during the hospital stay. Participants discharged in critical condition at the family's request are followed up by telephone. |
From randomization to hospital discharge, assessed up to 28 days
|
|
7-Day All-Cause Mortality
Временное ограничение: From randomization to day 7
|
Number of participants who die from any cause within 7 days after randomization. |
From randomization to day 7
|
|
28-Day All-Cause Mortality
Временное ограничение: From randomization to day 28
|
Number of participants who die from any cause within 28 days after randomization. |
From randomization to day 28
|
|
Number of Participants With Hypotension at CRRT Initiation or HA380 Cartridge Change
Временное ограничение: Within 30 minutes after CRRT initiation and after cartridge changes at 6, 12 and 18 hours
|
Hypotension defined as a decrease in mean arterial pressure (invasive monitoring) of more than 20% from the pre-connection value, or to <65 mmHg (<60 mmHg in patients aged ≥65 years), requiring an increase in vasopressor dose, within 30 minutes after connection of the CRRT circuit or after each HA380 cartridge change. |
Within 30 minutes after CRRT initiation and after cartridge changes at 6, 12 and 18 hours
|
|
Number of Participants With Bleeding Events
Временное ограничение: From initiation of CRRT to day 7
|
Treatment-emergent bleeding (catheter site, upper gastrointestinal or intracranial), identified by daily clinical monitoring and confirmed by investigations when clinically indicated, graded by CTCAE version 6.0. |
From initiation of CRRT to day 7
|
|
Number of Participants With Thrombocytopenia
Временное ограничение: From initiation of CRRT to day 7
|
Treatment-emergent thrombocytopenia defined as a platelet count decrease of ≥50% from baseline, severity graded by CTCAE version 6.0 according to the lowest platelet count. Platelet counts are obtained at baseline, day 3 and day 7, and whenever clinically indicated. |
From initiation of CRRT to day 7
|
|
Number of Participants With Hemolysis
Временное ограничение: From initiation of CRRT to day 7
|
Hemolysis defined as a hemoglobin decrease of ≥20 g/L with laboratory evidence of hemolysis (elevated LDH, decreased haptoglobin, and/or schistocytes on peripheral smear), graded by CTCAE version 6.0. Assessed by laboratory tests at baseline, day 3 and day 7, and whenever hemolysis is clinically suspected. |
From initiation of CRRT to day 7
|
|
Number of Participants With Electrolyte Disturbances
Временное ограничение: From initiation of CRRT until end of CRRT or day 7, whichever comes first
|
Treatment-emergent electrolyte disturbance defined as potassium <3.0 mmol/L, phosphate <0.6 mmol/L, ionized calcium <0.9 mmol/L or magnesium <0.5 mmol/L, graded by CTCAE version 6.0. |
From initiation of CRRT until end of CRRT or day 7, whichever comes first
|
|
Number of Participants With Hypothermia
Временное ограничение: From initiation of CRRT until end of CRRT or day 7, whichever comes first
|
Core temperature <35°C during CRRT, based on hourly core temperature monitoring (lowest value recorded every 6 hours in the first 24 hours, then daily), graded by CTCAE version 6.0. |
From initiation of CRRT until end of CRRT or day 7, whichever comes first
|
|
Number of Participants With Anaphylaxis
Временное ограничение: From initiation of CRRT to 72 hours
|
Anaphylaxis according to the Vietnamese Ministry of Health diagnostic criteria, graded by CTCAE version 6.0. |
From initiation of CRRT to 72 hours
|
|
Number of Participants With Catheter Occlusion
Временное ограничение: From initiation of CRRT to day 14
|
Dialysis catheter occlusion by clot requiring interruption of CRRT and catheter replacement. |
From initiation of CRRT to day 14
|
|
Number of Participants With Catheter-Site Infection
Временное ограничение: From initiation of CRRT to day 14
|
Swelling, erythema, discharge or pus within 2 cm of the dialysis catheter insertion site, graded by CTCAE version 6.0. |
From initiation of CRRT to day 14
|
|
Number of Participants With Catheter-Related Venous Thrombosis
Временное ограничение: From initiation of CRRT to day 14
|
Venous thrombosis related to the dialysis catheter, confirmed by ultrasound, graded by CTCAE version 6.0. |
From initiation of CRRT to day 14
|
|
Number of Participants With Extracorporeal Circuit Incidents
Временное ограничение: From initiation of CRRT until end of CRRT or 72 hours, whichever comes first
|
Number of participants with at least one device deficiency (ISO 14155:2026): hemofilter membrane rupture (blood leak alarm with pink/red effluent); M100 hemofilter clotting requiring unplanned circuit change (TMP >300 mmHg or unresolved clotting alarm, visible clot, or blood pump stopped by clot); early HA380 clotting requiring removal before 6 hours; or unplanned technical stoppage of the blood pump for ≥15 minutes. Each stoppage is attributed to one primary cause. The number of events per participant is also reported. |
From initiation of CRRT until end of CRRT or 72 hours, whichever comes first
|
Соавторы и исследователи
Следователи
- Главный следователь: Bui Viet Hoan, MD, The 108 Military Central Hospital
- Учебный стул: Pham Dang Hai, MD, PhD, The 108 Military Central Hospital
- Учебный стул: Le Xuan Duong, MD, PhD, The 108 Military Central Hospital
Публикации и полезные ссылки
Общие публикации
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
- Ranzani OT, Singer M, Salluh JIF, Shankar-Hari M, Pilcher D, Berger-Estilita J, Coopersmith CM, Juffermans NP, Laffey J, Reinikainen M, Neto AS, Tavares M, Timsit JF, Arias Lopez MDP, Arulkumaran N, Aryal D, Azoulay E, Celi LA, Chaudhuri D, De Lange D, De Waele J, Dos Santos CC, Du B, Einav S, Engelbrecht T, Fazla F, Ferrer R, Finazzi S, Fujii T, Gershengorn HB, Greene JD, Haniffa R, Hao S, Hasan MS, Hollenberg S, Ippolito M, Jung C, Kirov M, Kobari S, Lakbar I, Lipman J, Liu V, Liu X, Lobo SM, Magatti D, Martin GS, Metnitz B, Metnitz P, Myatra SN, Oczkowski S, Paiva JA, Paruk F, Pekkarinen PT, Piquilloud L, Polkki A, Prescott HC, Blaser AR, Rezende E, Robba C, Rochwerg B, Ruckly S, Samei R, Schenck EJ, Secombe P, Sendagire C, Siaw-Frimpong M, Simpkin AJ, Soares M, Summers C, Szczeklik W, Takala J, Tanaka S, Tricella G, Vincent JL, Wendon J, Zampieri FG, Rhodes A, Moreno R. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. JAMA. 2025 Dec 16;334(23):2090-2103. doi: 10.1001/jama.2025.20516.
- Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, Charpie JR, Hirsch JC. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010 Mar;11(2):234-8. doi: 10.1097/PCC.0b013e3181b806fc.
- Prescott HC, Antonelli M, Alhazzani W, Moller MH, Alshamsi F, Azevedo LCP, Belley-Cote E, De Waele J, Derde L, Dionne JC, Evans L, Gershengorn HB, Hodgson CL, Honarmand K, Kesecioglu J, McIntyre L, Mer M, Nunnally ME, Oczkowski SJW, Rochwerg B, Akinola OO, Akuamoah-Boateng KA, Alberto L, Angus DC, Arabi YM, Azoulay E, Cecconi M, Convocar PF, De Pascale G, Doi K, Du B, Egi M, Elie-Turenne MC, Ferrer R, Fox-Robichaud A, French C, Freund Y, Gong MN, Hale CP, Hammond NE, Hashmi M, Heunks L, Iwashyna TJ, Jacob ST, Klompas M, Kwizera A, Leeies M, Lejnieks JD, Levy MM, Machado FR, Maia MO, Masur H, Maves RC, McGloughlin S, McPeake J, Mohr NM, Myatra SN, Ostermann M, Peake SL, Pletz MW, Roberts JA, Rosa RG, Sawyer RG, Schorr CA, Simpson SQ, Weng L, Wiersinga WJ, Rhodes A, Coopersmith CM. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026 Apr 1;54(4):725-812. doi: 10.1097/CCM.0000000000007075. Epub 2026 Mar 23. No abstract available.
- Kotani Y, Di Gioia A, Landoni G, Belletti A, Khanna AK. An updated "norepinephrine equivalent" score in intensive care as a marker of shock severity. Crit Care. 2023 Jan 20;27(1):29. doi: 10.1186/s13054-023-04322-y.
- An Y, Guo Y, Zhou W, He Q, Li Z, Sui X, Yi X, Yi H. HA380 Hemoperfusion Combined with Continuous Veno-Venous Hemodiafiltration for the Treatment of Septic Shock. Bioengineering (Basel). 2025 Apr 9;12(4):400. doi: 10.3390/bioengineering12040400.
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Патологические процессы
- Мужские мочеполовые заболевания
- Заболевания почек
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Инфекции
- Синдром системного воспалительного ответа
- Воспаление
- Почечная недостаточность
- Шок
- Патологические состояния, признаки и симптомы
- Острое повреждение почек
- Сепсис
- Шок, септик
- Терапия
- Хирургические процедуры, оперативные
- Экстракорпоральная циркуляция
- Почечная заместительная терапия
- Непрерывная заместительная почечная терапия
Другие идентификационные номера исследования
- 7197/GCN-BV
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Individual participant data will not be made publicly available because consent for public data sharing was not obtained in this single-center study. Aggregate results will be published in peer-reviewed journals and reported on ClinicalTrials.gov.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .